K. Misiura et al. / Bioorg. Med. Chem. Lett. 12 (2002) 427–431
431
7. (a) Bruggmann, S. K.; Kisro, J.; Wagner, T. Cancer Res.
1997, 57, 2676. (b) Borner, K.; Kisro, J.; Bruggemann, S. K.;
Hagenah, W.; Peters, S. O.; Wagner, T. Drug Metab. Dispos.
2000, 28, 573.
8. Higgins, L.; Bennett, G. A.; Shimoji, M.; Jones, J. P. Bio-
chemistry 1998, 37, 7039.
mL). Organic solutions were combined, dried with Na2SO4,
concentrated and redissolved in ethyl acetate (0.2 mL), mixed
with trifluoroacetyl anhydride (0.2 mL), and heated at 80oC
for 20 min. After that time solutions were cooled down, con-
centrated and redissolved in ethyl acetate (100 mL). Obtained
samples were analysed on GC–MS.
9. Misiura, K.; Kinas, R. W.; Stec, W. J.; Kusnierczyk, H.;
Radzikowski, C.; Sonoda, A. J. Med. Chem. 1988, 31, 226.
10. Kusnierczyk, H.; Radzikowski, C.; Paprocka, M.; Bud-
zynski, W.; Rak, J.; Kinas, R. W.; Misiura, K.; Stec, W. J. J.
Immunopharmacol. 1986, 8, 455.
11. Glazman-Kusnierczyk, H.; Matuszyk, J.; Radzikowski, C.
Immunopharmacol. Immunotoxicol. 1992, 14, 883.
12. Misiura, K.; Kinas, R. W.; Kusnierczyk, H.; Radzi-
kowski, C.; Stec, W. J. Anti-Cancer Drugs 2001, 12, 453.
13. Kobylinska, K.; Koralewski, P.; Sobik, B.; Gasiorek, X.;
Kobylinska, M. Arzneim. Forsch. Drug Res. 2001, 51, 600.
14. Pankiewicz, K.; Kinas, R.; Stec, W. J.; Foster, A. B.; Jar-
man, M.; Van Maanen, J. M. S. J. Am. Chem. Soc. 1979, 101,
7712.
19. Fenselau, C. Anal. Chem. 1977, 49, 563A.
20. Sample (5 mL) was injected into OV 17 column (3%,
Chromosorb Q, 2.7 m) working at 240 ꢁC.
21. Antitumour effect of examined agents was evaluated in
vivo after single-dose treatment (day 3 only) of mice bearing
L1210 leukaemia. CDF1 mice were inoculated ip with 105
ascitic tumour cells suspended in 0.2 mL of PBS. The experi-
ments were conducted and activity of tested compounds was
evaluated according to the NIH/NCI in vivo standard
screening protocols. Effective doses providing 50% increase
of lifespan of treated animals over control (ED50) were esti-
mated graphically from the least square-fitted dose–effect
curves.
22. Sub-acute toxicity (45-day observation period) of com-
pounds IF, BF, (S)-(ꢀ)-BF and (S)-(ꢀ) BF-d4 was evaluated
in healthy CD2F1 females, 12–16 weeks old and weighing 25–
27 g. Mice were injected once by ip route or were given one
oral gavage (po route) of tested compounds. Mortality dis-
tribution was cumulated from three to six separate experi-
ments in which usually four to seven dose levels were used,
with at least five mice in a group. The log/dose–expected effect
curves were constructed according to Litchfield–Wilcoxon
method, based on the mortality distribution during observa-
tion period. Doses lethal for 50% of animals (LD50) as well as
LD5 maximally tolerated dose (MTD) were estimated graphi-
cally from the constructs and 95% confidence limits were cal-
culated for LD50. All computations were performed using CSS
Statistica software (StatSoft).
15. Sato, T.; Ueda, H.; Nakagawa, K.; Bodor, N. J. Org.
Chem. 1983, 48, 9 8.
1
16. All new compounds were fully characterised with H and
31P NMR and with MS.
17. (a) Connors, T. A.; Cox, P. J.; Farmer, P. B.; Foster, A. B.;
Jarman, M. Biochem. Pharmacol. 1974, 23, 115. (b) Foster,
A. B.; Jarman, M.; Kinas, R. W.; van Maanen, J. M.; Taylor,
G. N.; Gaston, J. L.; Parkin, A.; Richardson, A. C. J. Med.
Chem. 1981, 24, 1399.
18. Solutions of IF-d4 or IF (0.4 mM, 10 mL) in 0.1 M Tris–
HCl, pH 7.4, containing: 5 mM MgCl2, 6 mM glucose-6-
phosphate, 0.3 mM NADP, glucose-6-phosphate dehydro-
genase (0.8 U/mL) and active or inactive microsomes equiva-
lent to 1 g of rat liver were incubated in oxygen atmosphere at
37 ꢁC for 5, 10, 20 and 50 min. After each time a sample was
removed (2 mL) and chilled in ice. After addition of the 0.4
mM solution of cyclophosphamide in 0.1 M Tris–HCl, pH 7.4
(0.2 mL), each sample was extracted with ethyl acetate (3 ꢂ 3
23. Misiura, K.; Kardacka, K.; Kusnierczyk, H. Arch. Pharm.
Pharm. Med. Chem. 2001, 334, 291.
24. Huang, Z.; Roy, P.; Waxman, D. J. Biochem. Pharmacol.
2000, 59, 961.